NYSE:GMED - Globus Medical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Globus Medical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $53.32 -0.20 (-0.37 %) (As of 01/29/2020 10:32 AM ET) Add Compare Today's Range$53.02Now: $53.33▼$53.8650-Day Range$52.66MA: $56.43▼$59.4752-Week Range$38.37Now: $53.33▼$60.15Volume114,863 shsAverage Volume494,320 shsMarket Capitalization$5.30 billionP/E Ratio36.78Dividend YieldN/ABeta0.96 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Globus Medical, Inc, a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its spine product portfolio includes a range of implant and surgical approach options that could be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. Read More… Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:GMED Previous Symbol CUSIP37957720 CIK1237831 Webhttp://www.globusmedical.com/ Phone610-930-1800Debt Debt-to-Equity RatioN/A Current Ratio6.71 Quick Ratio4.74Price-To-Earnings Trailing P/E Ratio36.78 Forward P/E Ratio31.18 P/E Growth2.68 Sales & Book Value Annual Sales$712.97 million Price / Sales7.44 Cash Flow$2.19 per share Price / Cash Flow24.40 Book Value$12.03 per share Price / Book4.43Profitability EPS (Most Recent Fiscal Year)$1.67 Net Income$156.47 million Net Margins19.03% Return on Equity13.09% Return on Assets12.06%Miscellaneous Employees1,800 Outstanding Shares99,410,000Market Cap$5.30 billion Next Earnings Date2/20/2020 (Confirmed) OptionableOptionable Receive GMED News and Ratings via Email Sign-up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter. GMED Rates by TradingView Globus Medical (NYSE:GMED) Frequently Asked Questions What is Globus Medical's stock symbol? Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED." How were Globus Medical's earnings last quarter? Globus Medical Inc (NYSE:GMED) posted its quarterly earnings data on Wednesday, November, 6th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.42 by $0.01. The medical device company had revenue of $196.22 million for the quarter, compared to the consensus estimate of $185.86 million. Globus Medical had a return on equity of 13.09% and a net margin of 19.03%. The business's revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.39 EPS. View Globus Medical's Earnings History. When is Globus Medical's next earnings date? Globus Medical is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Globus Medical. What guidance has Globus Medical issued on next quarter's earnings? Globus Medical updated its FY20 earnings guidance on Wednesday, January, 8th. The company provided earnings per share guidance of $1.82 for the period, compared to the Thomson Reuters consensus estimate of $1.92. The company issued revenue guidance of $850.00 million, compared to the consensus revenue estimate of $854.27 million. What price target have analysts set for GMED? 9 brokers have issued twelve-month target prices for Globus Medical's shares. Their forecasts range from $60.00 to $67.00. On average, they expect Globus Medical's share price to reach $64.43 in the next year. This suggests a possible upside of 20.9% from the stock's current price. View Analyst Price Targets for Globus Medical. What is the consensus analysts' recommendation for Globus Medical? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Globus Medical. What are Wall Street analysts saying about Globus Medical stock? Here are some recent quotes from research analysts about Globus Medical stock: 1. According to Zacks Investment Research, "Globus Medical witnessed strength in the United States and the international regions as well as in the Musculoskeletal solutions and Enabling Technologies segments. Implant pull-through from ExcelsiusGPS placements and back-to-back record sales force recruiting years were the primary growth drivers. Internationally, spine business grew by 15% in the third quarter, ahead of the market in almost all significant geographies.Globus Medical posted mixed third-quarter results with earnings meeting the Zacks Consensus Estimate and revenues beating the mark.Globus Medical has outperformed its industry in the past three months. However, the pricing scenario is persistently tough for Globus Medical." (12/13/2019) 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating on GMED with a 12-month price target of $60. We think GMED has several top-line growth drivers, including a US core market rebound, early success of emerging technologies and traction of the acquired ATEC international platform. GMED’s best-in-class profitability allows the company to invest organically or inorganically to drive top-line growth and to react to the evolving trends of the spine market. These should bring the company back to the beat-and-raise philosophy of a couple of years ago and help to push the valuation higher." (3/1/2019) Has Globus Medical been receiving favorable news coverage? News headlines about GMED stock have trended negative on Wednesday, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Globus Medical earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave media stories about the medical device company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the near term. View News Stories for Globus Medical. Who are some of Globus Medical's key competitors? Some companies that are related to Globus Medical include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE). What other stocks do shareholders of Globus Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include AbbVie (ABBV), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY), Alibaba Group (BABA), Novartis (NVS), Intuitive Surgical (ISRG), Bausch Health Companies (BHC), Johnson & Johnson (JNJ), Pfizer (PFE) and Intel (INTC). Who are Globus Medical's key executives? Globus Medical's management team includes the folowing people: Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 52)Mr. David M. Demski, CEO & Director (Age 61)Mr. Anthony L. Williams, Pres & Corp. Sec. (Age 48)Mr. David D. Davidar, Co-Founder & Director (Age 53)Mr. Daniel T. Scavilla, CFO, Exec. VP & Chief Commercial Officer (Age 54) Who are Globus Medical's major shareholders? Globus Medical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Marathon Asset Management LLP (0.68%), Boston Trust Walden Corp (0.43%), Retirement Systems of Alabama (0.31%), California Public Employees Retirement System (0.17%), Meritage Portfolio Management (0.16%) and Zeke Capital Advisors LLC (0.14%). Company insiders that own Globus Medical stock include Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz, James R Tobin, Kelly Huller and Steven Payne. View Institutional Ownership Trends for Globus Medical. Which major investors are selling Globus Medical stock? GMED stock was sold by a variety of institutional investors in the last quarter, including Marathon Asset Management LLP, Retirement Systems of Alabama, Zeke Capital Advisors LLC, California Public Employees Retirement System, Virginia Retirement Systems ET AL, Arizona State Retirement System, Meritage Portfolio Management and Conservest Capital Advisors Inc.. Company insiders that have sold Globus Medical company stock in the last year include Anthony L Williams, David D Davidar, James R Tobin and Kelly Huller. View Insider Buying and Selling for Globus Medical. Which major investors are buying Globus Medical stock? GMED stock was purchased by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Dupont Capital Management Corp, Compass Ion Advisors LLC, Bridge City Capital LLC, Boston Trust Walden Corp, Cerebellum GP LLC, Strs Ohio and New York State Teachers Retirement System. View Insider Buying and Selling for Globus Medical. How do I buy shares of Globus Medical? Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Globus Medical's stock price today? One share of GMED stock can currently be purchased for approximately $53.30. How big of a company is Globus Medical? Globus Medical has a market capitalization of $5.30 billion and generates $712.97 million in revenue each year. The medical device company earns $156.47 million in net income (profit) each year or $1.67 on an earnings per share basis. Globus Medical employs 1,800 workers across the globe.View Additional Information About Globus Medical. What is Globus Medical's official website? The official website for Globus Medical is http://www.globusmedical.com/. How can I contact Globus Medical? Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected] MarketBeat Community Rating for Globus Medical (NYSE GMED)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 468 (Vote Outperform)Underperform Votes: 387 (Vote Underperform)Total Votes: 855MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe GMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMED will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/29/2020 by MarketBeat.com StaffFeatured Article: What are no-load funds?
